key: cord-0820362-rwlc5jgc
authors: Hanson, A.; Cohen, H.; Wang, H.; Shekhar, N.; Shah, C.; Dhaneshwar, A.; Harvey, B. W.; Murray, R.; Harvey, C. J.
title: Impaired ICOS signaling between Tfh and B cells distinguishes hospitalized from ambulatory CoViD-19 patients
date: 2020-12-18
journal: nan
DOI: 10.1101/2020.12.16.20248343
sha: b1f3102b3438b89b5ea1bdec7c755eb8319983dc
doc_id: 820362
cord_uid: rwlc5jgc

Emerging evidence suggests that SARS-CoV-2 infections are characterized by systemic immune responses that appear to be dysregulated with more severe CoViD-19 disease. Lymphopenia and delayed antibody responses are commonly identified in CoViD-19 subjects, and recent reports have demonstrated abrogation of germinal centers in severe CoViD-19. This work assessed a potential mechanistic basis for impaired humoral responses, focusing on the T follicular helper (Tfh) and B cell interface that is critical for germinal center reactions. Here we demonstrated that Tfh activity is impaired in hospitalized relative to ambulatory CoViD-19 subjects, potentially due to decreased expression of the costimulatory molecule ICOS-L on B cells. Functional impairment manifested as a diminished ability to stimulated Tfh derived IFNg; and IL-21, the latter of which is critical for B cell proliferation and differentiation. Activation of Tfh cells by agonism of the ICOS receptor ex vivo by an agonistic antibody stimulated the generation of IFNg/IL-21 double positive cells from hospitalized CoViD-19 subjects. This report establishes an immunological defect that differentiates ambulatory from hospitalized CoViD-19 and suggests that agents that could restore impaired mechanisms at the Tfh-B cell interface may be of therapeutic value.

The emergence of the SARS-CoV-2 virus from zoonotic transmission and the ensuing CoViD-19 pandemic 26 has resulted in approximately 61.3 million cases and over 1.44 million deaths globally as of November 27, 2020 1 . 27

Aberrant activation or dysfunction of the immune system as it relates to progressive CoViD-19 disease has been the 28 focus of recent investigations 2, 3, 4, 5, 6, 7, 8, 9 . The adaptive immune response is driven by the activity of T and B 29 lymphocytes, and a consistently observed immunological feature of progressive disease has been a negative 30 association of both T and B cell frequencies with increasing CoViD-19 severity 2, 3, 4, 5, 7, 9 . This reduction in 31 lymphocyte populations may contribute to a protracted course of disease and the delayed or absent humoral immune 32 response observed in severe cases. 33

Assessment of T cell responses have demonstrated a progressive decline in overall CD3+ T cells, and 34 consensus across studies points to the decline occurring in both CD4 and CD8 T cell populations 3 . This decrease is 35 consistently observed in a number of infectious diseases, including pandemic influenza; however, the duration of 36 lymphopenia is significantly longer in 11 . Despite the decreasing frequencies and prolonged 37 lymphopenic state of CoViD-19 subjects, generation of antigen-specific T cell responses appears to be intact as viral 38

CD4 and CD8 responses have been detected in virtually all convalescent subjects 6, 8 . 39 While memory T cells maintain their activity, initiation of B-cell mediated immune responses appears to be 40 delayed and also short-lived 9, 12, 13, 14 . CD4 Tfh cells are the critical cell type for initiating germinal center reactions 41 and stimulating the humoral response to viral pathogens. Limited data to date have suggested that Tfh cells are 42 increased within the CD4 compartment in CoViD-19 subjects 3, 7, 9 . The paradoxical increase in Tfh cells coupled 43 with B cell lymphopenia and delayed antibody responses suggest impairment of germinal center responses. The 44 absence of intact germinal centers in severe CoViD-19 cases has been recently demonstrated in studies where 45 pathological assessment of hilar lymph nodes in autopsied subjects as well as in lymph node and spleen biopsies 46 from infected subjects were performed 15, 16 . Among the mechanisms critical for germinal center formation, in both 47 animal systems and in humans, it is well established that the ICOS-L / ICOS signaling pathway plays a critical role 48 17, 18, 19, 20, 21, 22, 23 . In this study, we set forth to examine peripheral blood Tfh and B cells in samples from human 49

CoViD-19 donors of various disease severity to elucidate functional capacity and identify mechanisms of any 50 observed defect that may be contributing to the discordant observations of Tfh activation but impaired GC activity in 51

CoViD-19, with the ultimate goal of identifying actionable therapeutic targets. 52

Peripheral Blood Phenotyping Suggests Altered Tfh/B Cell Axis and Impaired Co-Stimulation 55

Three cohorts were used as part of this study and represented CoViD-19-naïve donors (Healthy Donors), 56 ambulatory CoViD-19 donors (Ambulatory), and hospitalized CoiViD-19 donors (Hospitalized). Detailed 57 description of study cohorts is provided in the supplemental material and in Table S1 . Flow cytometry-based 58 immunophenotyping of samples from all three cohorts was performed to assess the frequencies of immune cell 59 populations within the peripheral blood compartment compared to published findings. Consistent with the literature, 60 flow profiling demonstrated a reduction in CD19+ B cells, with decreases observed in both Ambulatory (mean 61 frequency of 6.2% of leukocytes) and Hospitalized cohorts (mean frequency of 8.8% of leukocytes) relative to 62 healthy donors (phenotyping cohort; mean frequency of 12.6% of total leukocytes) (Fig. 1A) . No significant 63 changes were observed within CD8 T cells (CD3+ CD19-CD4-) (Fig. 1C) , however a significant decrease in CD4 T 64 cells (from mean frequency of 32.8% to 17.7% of total leukocytes, Fig. 1D ) and corresponding trend towards an 65 increase in CD3-CD19-monocytes (from mean of 39.2% to 59.6%, Fig. 1B CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint T cell and B cell populations are interdependent on a variety of levels, and Tfh cells, specifically, are 75 critical mediators of antiviral B cell responses 18, 21, 22, 23 . As established in influenza infection and vaccination,  76   circulating Tfh populations are an induced, transient, and antigen specific population of CD4 T cells whose presence  77 correlates to long-term antibody responses and protection from either re-infection or infection following vaccination. 78

To assess whether circulating Tfh (cTfh) cell populations are changing within CoViD-19 subjects, phenotypic 79 profiling, including assessment of activation status was performed on peripheral blood mononuclear cells (PBMCs) . 80

This analysis demonstrated a significant enrichment of cTfh cells (defined as CD3+ CD4+ CXCR5+ ICOS+ 81 lymphocytes) within Ambulatory subjects and encompassed on average 15% of the peripheral blood CD4 82 compartment relative to the 8% cTfh population observed in healthy donors ( Fig. 2A ). This increase, however, was 83 limited to the Ambulatory cohort, and cTfh cells were significantly decreased relative to both healthy donors and 84

Ambulatory CoViD-19 subjects and represented only 2% of CD4 T cells in Hospitalized subjects. To assess 85 whether age may be confounding the observed differences in Tfh frequency, cellular phenotype and frequency were 86 assessed in age matched healthy donor cohorts, and no decrease was observed in age-matched healthy donor 87 subjects (Fig. S3) , indicating that the reduction in Hospitalized CoViD-19 subject Tfh cells does not appear to be 88 generally age-related. 89

Within the Hospitalized CoViD-19 donors, the observed decrease in peripheral CD4 T cells and B cell 90 populations may be due to a significant alteration of the Tfh/B cell axis in severe disease. To test this hypothesis, 91 assessment of various mechanisms that may contribute to defective Tfh/B cell activation were interrogated. Tfh-92 mediated B cell activation is primarily driven by three distinct processes: antigen-presentation by B cells or other 93 APC, B-cell mediated co-stimulation of T cells, and cytokine-driven B cell activation and differentiation. 94 lower on a per-cell basis (Fig. 2E ). Together, the data suggest intact antigen presentation capacity within CoViD-19 100 subjects, and both HLA-DR+ monocytes and B cells appear capable of presenting viral antigens to stimulate initial 101 TCR priming. 102 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10. 1101 To further drive T cell responses, co-stimulation is necessary, as the absence of co-stimulation can drive 103 anergy 24 . Studies examining the Tfh-B cell entanglement within the germinal centers have demonstrated a critical 104 role for the ICOS/ICOS-L pathway for driving the development of humoral responses 21 . B cell expressed ICOS-L 105 activates the co-stimulatory receptor ICOS on CD4 Tfh cells, which in turn has been shown to drive a feed-forward 106 mechanism to promote B cell activation and differentiation through a variety of accessory molecules, including 107 CD40L and the cytokine 20, 21, 22, 25 . Profiling of cTfh cells demonstrated increased ICOS+ Tfh cells within 108 Ambulatory cohorts but a significant reduction in more severe subjects. To assess for potential defects in co- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248343 doi: medRxiv preprint

As Tfh-B cell entanglement is driven by signaling in both directions, intrinsic defects in Tfh cells could 140 mediate the lack of B cell response in severe disease. To assess the fundamental capability of peripheral blood Tfh 141 cells to respond to TCR activation and co-stimulation, CD4 T cells from healthy donor, Ambulatory, and 142

Hospitalized cohorts were activated with a standard combination of anti-CD3 and anti-CD28 antibodies. Following 143 stimulation, the ability of Tfh cells to produce the effector cytokines IL-21 and IFNγ was assessed by flow 144 cytometry. To account for observed decreases in the fraction of CD4 T cells in the peripheral blood of Hospitalized 145

CoViD-19 patients, the data was examined two ways: both as polyfunctional cells as a percent of cTfh as well as 146 polyfunctional cells as a percent of total leukocytes to account for lymphocyte changes between subjects and 147 cohorts. Intracellular staining demonstrated a strong and significantly elevated polyfunctional cytokine response in 148 the Ambulatory cohort, with IL-21+ IFNγ+ Tfh cells encompassing mean of 35% of total cTfh cells relative to 8% 149 in the Hospitalized cohort, which represents a four-fold reduction (Fig. 3A) . When assessed as a fraction of total 150 leukocytes, polyfunctional cTfh cells were significantly elevated in the Ambulatory cohort and represented a mean 151 of 2% of total leukocytes (Fig. 3B ). In contrast, polyfunctional cTfh cells only accounted for a mean of 0.03% of 152 total leukocytes in Hospitalized CoViD-19 subjects, representing an average of 67-fold reduction relative to the 153 Ambulatory cohort. Relative to age-matched healthy donor subjects, no expansion of polyfunctional cTfh cells was 154 observed in Hospitalized CoViD-19 subjects (Fig. 3B ). Similar trends are observed in the frequencies of cTfh cell 155 expressing single cytokines, and data are shown in Figure S4 . These data reveal a diminished capacity to produce 156 IL-21 alone or in combination with IFNγ within Tfh cells of Hospitalized donors. IL-21 is a key cytokine for Tfh-157 mediated B cell responses, and its expression has been demonstrated to be regulated by ICOS-driven increases in c-158

Maf expression. In Hospitalized CoViD-19 donors, the failure to upregulate ICOS-L expression on B cells and the 159 corresponding lack of IL-21 production by Tfh cells may mechanistically contribute to the diminished humoral 160 response associated with severe disease. 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248343 doi: medRxiv preprint 

To assess if exogenous ICOS co-stimulation may enhance cytokine production within Tfh cells of CoViD-172 19 donors, a parallel experiment as above was performed where peripheral blood mononuclear cells (PBMCs) were 173 stimulated with a combination of sub-optimal anti-CD3 and saturating anti-CD28 or sub-optimal anti-CD3 and 174 saturating anti-ICOS agonist antibody. The concentration of anti-CD3 used was sufficient to induce T cell 175 activation but not induce proliferation or cytokine secretion on its own, providing a window to assess the effects of 176 specific co-stimulation. After a 24hr incubation, expression of the effector cytokines IL-21 and IFNγ was assessed 177 by flow cytometry. Similar to the previous experiment, robust cytokine responses were observed in the Ambulatory 178 cohort, but a significant reduction in frequency of cells expressing both IL-21and IFNγ (Fig. 4A ) was observed in 179 the Hospitalized cohort with CD28 co-stimulation. In contrast to CD28, co-stimulation through ICOS resulted in a 180 significant increase in the fraction of IL-21+ IFNγ+ Tfh cells (6-fold increase) in Hospitalized subjects (Fig. 4A) . 181 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10. 1101 When examined across Ambulatory and Hospitalized cohorts, co-stimulation through ICOS resulted in 182 polyfunctional cytokine expression by Tfh cells that was similar to the fraction observed in Ambulatory subjects as a 183 trend towards elevated frequency of polyfunctional cTfh cells in hospitalized relative to ambulatory subjects was 184 observed following ICOS agonism (Fig. 4A) . Similar increases in cTfh cells producing a single-cytokine was also 185 observed ( Fig. S4C-D This in vitro activity has carried over to the clinic, where treatment with an ICOS agonist in the setting of oncology 231 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 18, 2020. demonstrated an ability to expand and maintain cTfh cells as well as Th1 and Tcm cells in the peripheral blood of 232 long-term responders 33 . Oncology studies provide precedent for testing a mechanism observed in the clinic that 233 may be advantageous in boosting immune responses in the setting of hospitalized CoViD-19 subjects where natural 234 B-cell mediated co-stimulation is deficient. The lack of co-stimulation may result not only in the absence of a 235 necessary second signal for a durable immune response, but also exacerbate the lymphopenia as constant TCR 236 stimulation in the absence of co-stimulation has been shown to result in T cell apoptosis 34, 35 . Overall, the data 237 suggest providing additional co-stimulation to the ICOS pathway may help restore and maintain a holistic humoral 238 immune response, particularly in scenarios in which ICOS-L expression appears defective. 239

Study populations 242

Three cohorts were identified for the study. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ;

Informed consent was obtained and documented for all subjects enrolled. 260 261

Peripheral blood samples from the Ambulatory and Hospitalized cohorts were collected directly into 8mL 263 sodium heparin CPT tubes using a BD 70vacutainer safety-lok blood collection system and processed according to 264 manufacturer's instructions with the following modifications. Immediately after collection the CPT tube was gently 265 inverted 10 times to mix the anticoagulant with the blood. CPT tubes were then spun at 1800g for 15 min. at 22°Cin 266 a swing bucket centrifuge, cell and plasma fractions were then decanted into a 15mL Falcon tube and spun at 300g 267 for 15 min. at 22°C. Supernatant was decanted, and the cell pellet was re-suspended in 1mL freezing media (10% 268 DMSO in FBS) and transferred via pipet to a 1.8mL cryovial. Cryovials were immediately placed in a room 269 Permeabilized cells were stained with biotinylated anti-human ICOS antibody (clone: M13, Jounce Therapeutics) 295 for 30min at RT. Cells were washed and then stained with streptavidin-BV421 for 30min, RT. After washing, cells 296

were re-suspended in flow buffer and flow cytometry was performed using the LSR Fortessa (BD). 297

Plate bound antibody conditions were prepared as follows: In 1X PBS in a 96 well round bottom TC plate, 300 plate bound anti-human CD3 (clone: OKT3, BioXCell) was coated at a final sub-optimal stimulation concentration 301 of 1ug/ml with either plate bound anti-human CD28 (clone:CD28.2, Biolegend) at a final concentration of 10ug/ml, 302 or 10ug/ml final concentration of anti-human ICOS (clone: 36E10, Jounce Therapeutics) for 2 hours at 37C. Plates 303 were washed with 1X PBS to remove un-bound antibody and cells were plated at .25x10^6 cells/ well, in triplicate, 304 from ambulatory COVID subjects, or hospitalized COVID subjects. At this time, age representative younger and 305 older normal donor (pre-COVID collection) PBMCs were also plated at .25x10^6 cells/ well, in triplicate in 306 untreated wells of a 96 round bottom TC plate in the presence of CD3/CD28 beads (Gibco) at a 3:1 bead to T cell 307 ratio, assuming ~60% T cell composition within each well. Beads were prepared for plating according to 308 manufacturer's instructions. All plates were then incubated for 24hr at 37C. Brefeldin A (Biolegend) and monensin 309 (Biolegend) were added according to manufacturer's instructions for the final five to six hours of the incubation. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248343 doi: medRxiv preprint eFluor780 fixable viability dye (eBioscience) for 30 min at 4⁰C. After washing with flow buffer, cells were 317 permeabilized and fixed using the FOXP3 Fixation/Permeabilization Concentrate and Diluent Kit (eBioscience) 318 according to the manufacturer's instructions. Permeabilized cells were stained with biotinylated anti-human ICOS 319 antibody (clone: M13, Jounce Therapeutics), IL-21-PE (clone: 3A3-N2, Biolegend), and IFNg-BV605 (clone:B27, 320

Biolegend) for 30 min, RT. Cells were then washed and stained with streptavidin-BV421 for 30min, RT. After 321 washing, cells were re-suspended in flow buffer and flow cytometry was performed using the LSR Fortessa (BD). 322 RT. After washing, cells were re-suspended in flow buffer and flow cytometry was performed using the LSR 340 Fortessa (BD). Samples acquisition was performed by transferring cells from the 96 well round bottom staining plate 341 to a 5ml FACS tube and running each sample dry. 342 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248343 doi: medRxiv preprint

All statistical analyses were performed in Prism (GraphPad Software). Comparison of the distribution of 344 frequencies of cell phenotypes between cohorts was performed using the Kolmogorov-Smirnov test. Assessment of 345 stimulation-induced changes were performed using a Wilcoxon Signed-rank test. A p value of < 0.05 was deemed 346 significant. Calculated p values are indicated in graphs where the difference was statistically significant. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10. 1101 

CoViD-19 Dashboard

Clinical and immunological features of severe and moderate coronavirus disease 2019

T cell responses in patients with COVID-19

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients 377 with COVID-19 pneumonia

Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected 383 controls

Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct 386 immunotypes with implications for therapeutic interventions. bioRxiv

Robust T cell immunity in convalescent individuals with asymptomatic or mold COVID-389 19. bioRxiv

Breadth of concomitant immune responses prior to patient recovery: a case report of 392 non-severe COVID-19

Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and 395 aberrant CD8 responses

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Distinct early serological signatures track with SARS-CoV-2 survival

Kinetics of viral load and antibody response in relation to COVID-19 severity

Dissecting antibody-mediated protection against SARS-CoV-2

Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients

The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal 412 Centers in COVID-19

Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus 424 and parasite infection

T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction

ICOS is critical for CD40-mediated antibody class switching

Loss of human ICOSL results in combined immunodeficiency

Duration of TCR stimulation determines costimulatory requirement of T cells

Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during 439 CD4+ T cell-B cell collaboration

ICOS deficiency in patients with common variable immunodeficiency

Human ICOS deficiency abrogates the germinal center reaction and provides a 445 monogenic model for common variable immunodeficiency

The quantity of CD40 signaling determines the differentiation 448 of B cells into functionally distinct memory cell subsets

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery

Lack of peripheral memory B cell responses in recovered patients with severe acute 457 respiratory syndrome: a six-year follow-up study

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-460 linking for optimal T cell activation and anti-tumor immunity in preclinical models

Abstract 5536: ICOS hi CD4 T cells emerging on vopratelimab treatment have Th1, Tcm, 463 and Tfh characteristics and may contribute to durability of clinical responses

A cell culture model for T lymphocyte clonal anergy

Induction of T-cell activation or anergy determined by the 468 combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an 469 individual cell

WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. R&D 472 Blueprint